ABSTRACT

Aim: To determine the Indian Practitioner's Perspective on the clinical efficacy and safety of Netilmicin (NETROMAX)

Materials & Methods: 105 practitioners, including surgeons, chest specialists, pediatricians and internal medicine specialists, throughout India collaborated in the recruitment of 202 patients over a period of 6 months. Patients with bacterial infections were administered Netilmicin (NETROMAX) as determined by the practitioner, and the practitioner's opinion on the clinical efficacy and safety were observed at the end of treatment duration.

Results: 161 patients were evaluable for efficacy of Netilmicin (NETROMAX). The most commonly employed regimen by the practitioners was administrating 300 mg Netilmicin (NETROMAX) I.V. once daily for up to 14 days. Favorable clinical response, as correlated with the practitioner's opinion, was observed in 94.4% of the patients. The opinion that Netilmicin (NETROMAX) provided excellent therapeutic, rather than only prophylactic, benefits to the infected patients was given by 57.55% of the practitioners. Netilmicin (NETROMAX) was well tolerated in the evaluable patients with only two patients (1%) complaining of adverse events.

Conclusion: Netilmicin (NETROMAX) was found to be a safe, well tolerated and useful aminoglycoside to treat a number of bacterial infections in current Indian scenario.